By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

The latest findings support the expectation that the combination therapy will become the new SOC in PD-L1-positive TNBC.

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.

GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard ...

Drugmaker stocks tend to trade at mid-single-digit multiples of trailing annual sales. Summit has no sales, as ivonescimab is ...

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...

Trodelvy, in combination with Keytruda, significantly lowers the risk of progression in triple-negative breast cancer by 35%, ...

Following Merus’ splash last month with a “best-in-disease profile” for its head and neck cancer bispecific, Bicara touted ...